Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Myelodysplastic Syndrome

6 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Other

    VICCPED1639

    09/28/2016

    Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

    Other

    VICCBMT1407

    04/17/2015

    A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome

    Treatment

    VICCHEM16146

    08/07/2017

    A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy with DNA Methyl Transferase Inhibitors

    Treatment

    VICCHEM1709

    08/01/2017

    A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

    Treatment

    VICCHEM16136

    05/10/2017

    A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    Treatment

    VICCHEMP1558

    10/09/2015

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies


    Print this page for your doctor